MethyPatch Clinical Data to be Presented at AACAP Annual Meeting

METHYPATCH^® CLINICAL DATA TO BE PRESENTED AT
AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY ANNUAL MEETING

ADHD Experts to Present Clinical Data on
Once-Daily Transdermal Methylphenidate Patch

MIAMI, FL. - October 3, 2001 - Noven Pharmaceuticals, Inc. (Nasdaq:NOVN) today announced that MethyPatch^®, Noven's once-daily transdermal methylphenidate system for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), will be the subject of a symposium to be held at the American Academy of Child & Adolescent Psychiatry (AACAP) Annual Meeting.

The symposium, entitled "Can a Once-Daily Methylphenidate Patch Help Children with ADHD?", is scheduled for 10:30 a.m. (Hawaii-Aleutian Time) on October 27, 2001, at the Hilton Hawaiian Village in Honolulu, Hawaii. The symposium will review the results of MethyPatch^® clinical trials completed to date. Scheduled presenters are Laurence L. Greenhill, M.D., Clinical Professor of Child Psychology, Columbia University; William E. Pelham, Ph.D., Professor of Psychology, Center of Children and Families, State University of New York at Buffalo; Donald R. Jasinski, M.D., Chief, Center for Chemical Dependents, John Hopkins Bayview Medical Center; and Mario A. Gonzalez, Ph.D., President & CEO, GloboMax Americas LLC.

Noven's once-daily MethyPatch^® is designed to offer the safety and efficacy of immediate release oral methylphenidate products, while eliminating in-school dosing and providing physicians and parents with the ability to discontinue dosing as needed by removing the patch. Noven expects to begin a supplemental Phase III clinical study of MethyPatch^® in the fall of 2001 at centers throughout the U.S.

ADHD affects 3% to 5% of school-age children, and an estimated 1.5 million children are currently on medication to treat this disorder. All presently approved ADHD medications are delivered orally. AACAP, established in 1953, is the leading national professional medical association dedicated to treating and improving the quality of life for children, adolescents, and families affected by these disorders. It is a membership based organization comprised of over 6,500 child and adolescent psychiatrists and other interested physicians. For more information about AACAP and the Annual Meeting, visit www.aacap.org.

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leader in the development of transdermal and transmucosal drug delivery technologies and products. Together with Novartis Pharmaceuticals Corporation, Noven owns a women's health products company called Novogyne Pharmaceuticals. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot™, licensed to Novogyne, and Estradot^®, licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatch^®, licensed to Novogyne, and Estalis^®, licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatch^®, Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal and transmucosal drug delivery systems. For additional information, visit Noven's website at www.noven.com.

Investor & Media Contact:
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
(305) 253-1916

Back